Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 4Phase 3 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 29INDUSTRY 18NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 67Sarcoma 63Other hematologic neoplasm 62Gastrointestinal 61CNS 61Genitourinary 48Dermatologic 44Thoracic 41Breast 35Gynecologic 30Head & Neck 26Plasma cell 19Myeloid 18Other solid neoplasm 14Classical hematology 10Endocrine 7Tumor-Agnostic 6Other neoplasm 3NET 1

Conditions

Neuroendocrine Tumors 1Carcinoid Tumor 1

Interventions

olaparib 1lutetium Lu 177 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × NIH × NET × Clear all
NCT04086485 2026-05-22

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
56 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡